早期抑郁症_SAGE-217治疗抑郁症的临床研究
Altered neurotransmission of -aminobutyric acid (GABA) has been implicated in the pathogenesis of depression. Whether SAGE-217, an oral, positive allosteric modulator of GABA type A receptors, is effective and safe for the treatment of major depressive disorder is unknown.
METHODSIn this double-blind, phase 2 trial, we enrolled patients with major depression and randomly assigned them in a 1:1 ratio to receive 30 mg of SAGE-217 or placebo once daily. The primary end point was the change from baseline to day 15 in the score on the 17-item Hamilton Depression Rating Scale (HAM-D; scores range from 0 to 52, with higher scores indicating more severe depression). Secondary efficacy end points, which were assessed on days 2 through 8 and on days 15, 21, 28, 35, and 42, included changes from baseline in scores on additional depression and anxiety scales, a reduction from baseline of more than 50% in the HAM-D score, a HAM-D score of 7 or lower, and a Clinical Global Impression of Improvement score of 1 (very much improved) or 2 (much improved) (on a scale of 1 to 7, with a score of 7 indicating that symptoms are very much worse).
RESULTSA total of 89 patients underwent randomization: 45 patients were assigned to the SAGE-217 group, and 44 to the placebo group. The mean baseline HAM-D score was 25.2 in the SAGE-217 group and 25.7 in the placebo group. The least-squares mean ( SE) change in the HAM-D score from baseline to day 15 was 17.4 1.3 points in the SAGE-217 group and 10.3 1.3 points in the placebo group (least-squares mean difference in change, 7.0 points; 95% confidence interval, 10.2 to 3.9; P 0.001). The differences in secondary end points were generally in the same direction as those of the primary end point. There were no serious adverse events. The most common adverse events in the SAGE-217 group were headache, dizziness, nausea, and somnolence.
CONCLUSIONSAdministration of SAGE-217 daily for 14 days resulted in a reduction in depressive symptoms at day 15. Adverse events were more common in the SAGE-217 group than in the placebo group. Further trials are needed to determine the durability and safety of SAGE-217 in major depressive disorder and to compare SAGE-217 with available treatments. (Funded by Sage Therapeutics; ClinicalTrials.gov number, NCT03000530. opens in new tab.)
期刊信息The New England Journal of Medicine:《新英格兰医学杂志》,创刊于1812年。隶属于麻省医学协会,最新IF:70.67
官方网址:
投稿链接:
您可能感兴趣
鎵嬫満鐓х墖鎭㈠绠″蹇犲憡:寰俊鍥剧墖灏辫繖涔?em>鎭㈠
手机照片恢复管家忠告:微信图片就这么恢复。手机的相机也由一个摄像头变成三摄甚至四摄,相机性能也是越来越好,我们手机相册的照片也是越...
[所向资本创始合伙人和平:投资人最重要的是,把智力和资源输出给...]
原标题:所向资本创始合伙人和平:投资人最重要的是,把智力和资源输出给正确的团队【猎云网北京】12月12日报道12月10日~11日,2019年度CE...